Diplomat Pharmacy Inc (NYSE:DPLO) Director Philip R. Hagerman sold 2,150,000 shares of the company’s stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $20.65, for a total transaction of $44,397,500.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Diplomat Pharmacy Inc (NYSE DPLO) traded down $0.02 on Monday, hitting $22.39. 635,574 shares of the company’s stock were exchanged, compared to its average volume of 974,424. The company has a market capitalization of $1,540.00, a price-to-earnings ratio of 65.85 and a beta of 1.32. Diplomat Pharmacy Inc has a fifty-two week low of $14.00 and a fifty-two week high of $27.78. The company has a current ratio of 0.97, a quick ratio of 0.66 and a debt-to-equity ratio of 0.70.
Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings results on Monday, February 26th. The company reported $0.18 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.16 by $0.02. Diplomat Pharmacy had a net margin of 0.35% and a return on equity of 8.89%. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.17 billion. During the same period in the prior year, the business posted $0.08 earnings per share. The company’s revenue was up .9% on a year-over-year basis. equities research analysts expect that Diplomat Pharmacy Inc will post 0.93 EPS for the current year.
A number of brokerages have commented on DPLO. Deutsche Bank cut shares of Diplomat Pharmacy from a “buy” rating to a “hold” rating and upped their target price for the company from $22.00 to $29.00 in a report on Friday, February 2nd. Credit Suisse Group raised shares of Diplomat Pharmacy from an “underperform” rating to a “neutral” rating and set a $28.00 target price for the company in a report on Thursday, January 25th. Mizuho set a $25.00 price target on shares of Diplomat Pharmacy and gave the stock a “hold” rating in a research report on Wednesday, January 24th. Zacks Investment Research lowered shares of Diplomat Pharmacy from a “buy” rating to a “hold” rating in a research report on Wednesday, February 21st. Finally, Lake Street Capital started coverage on shares of Diplomat Pharmacy in a research report on Friday, February 9th. They issued a “buy” rating and a $35.00 price target for the company. Eight analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $25.38.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.